Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 3 of 8

Merck entered the candidate drug, which it called MK-2640, into a phase 1 clinical trial that finished at the end of 2016

Development of Merck's candidate smart insulin MK-2640 has been terminated because of a lack of efficacy in phase I trials, but the company is moving forward with a back-up candidate